Last reviewed · How we verify
HDM1002
At a glance
| Generic name | HDM1002 |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin (PHASE1)
- Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (PHASE3)
- To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (PHASE2)
- A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (PHASE3)
- A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement (PHASE1)
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults (PHASE3)
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. (PHASE1)
- A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM1002 CI brief — competitive landscape report
- HDM1002 updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI